NovoStent raises $3m for anchored helical stent human trial:
This article was originally published in Clinica
NovoStent has raised an additional $3.1m in a second round of financing. The proceeds will be used to develop "more robust human data" on its proprietary "anchored" helical stent technology, which the Mountain View, California firm claims to offer better durability, flexibility and compression resistance than standard stent designs. The first human trial on NovoStent's device, involving the superficial femoral artery, is slated to start in 2006.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.